
Opinion|Videos|July 3, 2024
Gene Therapy for Treatment of Duchenne Muscular Dystrophy
Author(s)Emma Ciafaloni, MD
Focusing on gene therapy and exon skipping medications, an expert on Duchenne muscular dystrophy discusses current and emerging treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Provide an overview of delandistrogene moxeparvovec, micro-dystrophin gene therapy, that received accelerated approval for Duchenne muscular dystrophy (DMD) in 2023.
- Discuss ongoing studies for fordadistrogene movaparvovec gene therapy and other exon skipping therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM
2
FDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosis
3
Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action
4
FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis
5



















